news roundup
Saama Technologies and iNDX.Ai have launched COVID-19 Command Center, a data analytics platform of patient data from ongoing COVID-19 clinical trials in China, South Korea, and the U.S. The goal is to enable researchers to use the data to optimize study design, patient selection, site activation, and scientific analysis more quickly.
Clinical Ink has implemented a fee structure change for clients. Its Study Assurance Program is designed to minimize financial impact of the disruption from COVID-19 on new and existing clinical trials.
Certara and DMTC have entered into a research collaboration to evaluate the preventative use of chloroquine in health care workers at risk of infection from COVID-19. Certara will support the DMTC-led clinical trial by analyzing study data to develop mathematical models to understand the viral time course and factors impacting drug exposure and prophylactic response in health care workers.
|
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
Events
| Search Upcoming Events |
| |
|
advertisement
Bioforum, the Forum for EmergingBio's Outsourcing Decisions
As the biopharma industry traverses unchartered waters amid the COVID-19 crisis and doubles down on its efforts to bring new therapies to market faster, cheaper and without affecting quality, the success of strategic partnerships and functional service provider models will become more critical than ever before.
Read the article
|
|
|
|
|
|
|
|
|
|
|
|
|
Articles |
|
This article describes how Karyopharm Therapeutics used Komodo Health’s natural history platform of real-time patient data to identify hundreds of providers and institutions with the highest at-risk populations for its COVID-19 trial.
|
|
Charles River Associates shares insights from recent discussions with a selection of CRO, policy, regulatory, and venture capital experts to understand the implications of the pandemic on trials in the short- and long-term.
|
Blog Posts
Cures 2.0 continues and updates some of the main themes of the first Cures Act: support development of treatments for rare diseases, patient-focused drug development, diversity in clinical trials, expanded use of digital health systems, increased health literacy, and utilization of real-world data.
|
|
|
|
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
